Navigation Links
Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Date:12/18/2007

SAN DIEGO, Dec. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it entered into strategic cooperation agreements with Siegfried Ltd., an affiliate of Siegfried Holding AG (SWX: SFZN). The agreements primarily relate to the manufacturing of lorcaserin hydrochloride, which is expected to be necessary for Arena's planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) and for commercialization of lorcaserin after regulatory marketing approval. Lorcaserin is Arena's Phase 3 oral drug candidate being developed for the treatment of obesity. Arena expects that this transaction will close on January 8, 2008 and believes that it has the potential to:

-- Reduce manufacturing related risks to the lorcaserin NDA registration

lots and submission of its planned lorcaserin NDA.

-- Secure a long-term supply of lorcaserin active pharmaceutical

ingredient (API).

-- Reduce the overall manufacturing costs for lorcaserin and other Arena

product candidates.

-- Lead to significant future tax benefits, which may result from a

favorable tax ruling Arena received from Switzerland.

The agreements with Siegfried include the following:

-- A long-term supply agreement for Arena's purchase of lorcaserin API at

competitive rates for a period of 15 years after FDA approval.

-- An asset purchase agreement for Arena's purchase of certain finishing

facility assets and technology, including the transfer of certain

equipment, fixtures and real estate assets used in converting API into

tablet form, the expected finished drug product (FDP) of lorcaserin.

Approximate
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Isotope Ratio Mass Spectrometer Industry Report 2014" report ... Isotope Ratio Mass Spectrometer Industry Report 2014 is a ... the global isotope ratio mass spectrometer industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... 2014 Riviera Beach, Florida based ... creation of the Sancilio Scientific Advisory Board (SSAB). ... philosophy of looking to nature for pharmaceutical advancements, ... are based on sound scientific data, analyses, expertise ... provides a vehicle for SCI to receive peer ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/27/2014)... Hunting Valley, Ohio (PRWEB) August 27, 2014 ... five students from Cleveland's University School ... at Case Western Reserve University’s School of ... program provides students with an unparalleled professional experience ... with the School of Medicine faculty and students ...
Breaking Biology Technology:Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Monitorforhire.com, the,fastest source for hiring independent ... The company has added a mobile portal, ... to work requests via,PDA or cell phone ... president of monitorforhire.com says that adding the,capability ...
... in San Francisco on Wednesday, October ... ... 2 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... Officer, will present at the Biotechnology,Industry Organization (BIO) InvestorForum at 10:15 ...
... Sciences, a Roche,company, and Perlegen Sciences, Inc., today ... in hundreds of DNA samples,collected by Perlegen from ... of drug. The goal of the collaboration will ... identified and,validated to create a clinical test that ...
Cached Biology Technology:New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3
(Date:8/27/2014)... Outstanding basic research, a growing focus on translating ... care have earned the Herbert Irving Comprehensive Cancer ... and NewYork-Presbyterian Hospital an $18 million, five-year Cancer ... (NCI). The grant renews the center,s status as ... in New York City and one of only ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... ago the Happy Camp Complex of fires had consumed ... complex had consumed 35,530 as of eight hours ago. ... Happy Camp Ranger District of the Klamath National Forest ... 11, 2014. All but three of those fires are ... of contained fires and their size at containment: Delta, ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... being able to predict the risk of disease or response ... a study by scientists at Washington University School of Medicine ... alone only tell part of the story. That,s because ... to predict, even in simple organisms like single-celled yeast, their ...
... Virginia Commonwealth University Massey Cancer Center led by Charles ... Biology, discovered a previously unknown mechanism in non-small cell ... to maintain and grow tumors. Narrowing in on this ... effective therapies for NSCLC and other cancers. ...
... 2010, Seoul, S. Korea Institut Pasteur Korea (IP-K) ... of Toulouse, France to continue research on the identification ... up in the fall of 2009, illustrates the value ... platform will be used to pinpoint active, non-toxic agents ...
Cached Biology News:The gene-environment enigma 2The gene-environment enigma 3VCU Massey discovery could lead to breakthrough for non-small cell lung cancer 2
...
Contains L-glutamine....
... Resolution - Efficiently separates ... to 1000 bp. It ... PCR fragments, small DNA ... enzyme digestion, and double-stranded ...
...
Biology Products: